CD14(+) macrophages that accumulate in the colon of African AIDS patients express pro-inflammatory cytokines and are responsive to lipopolysaccharide by Cassol, Edana et al.
RESEARCH ARTICLE Open Access
CD14+ macrophages that accumulate in
the colon of African AIDS patients express
pro-inflammatory cytokines and are
responsive to lipopolysaccharide
Edana Cassol1,2*, Theresa Rossouw1,3†, Susan Malfeld1, Phetole Mahasha1, Tomas Slavik4, Chris Seebregts5,6,
Robert Bond7, Johannie du Plessis7, Carl Janssen7, Tania Roskams8, Frederik Nevens9, Massimo Alfano10,14,
Guido Poli10,11,12 and Schalk W. van der Merwe1,13†
Abstract
Background: Intestinal macrophages are key regulators of inflammatory responses to the gut microbiome and play
a central role in maintaining tissue homeostasis and epithelial integrity. However, little is known about the role of
these cells in HIV infection, a disease fuelled by intestinal inflammation, a loss of epithelial barrier function and
increased microbial translocation (MT).
Methods: Phenotypic and functional characterization of intestinal macrophages was performed for 23 African AIDS
patients with chronic diarrhea and/or weight loss and 11 HIV-negative Africans with and without inflammatory
bowel disease (IBD). AIDS patients were treated with cotrimoxazole for the prevention of opportunistic infections
(OIs). Macrophage phenotype was assessed by flow cytometry and immuno-histochemistry (IHC); production of
proinflammatory mediators by IHC and Qiagen PCR Arrays; in vitro secretion of cytokines by the Bio-Plex Suspension
Array System. Statistical analyses were performed using Spearman’s correlation and Wilcoxon matched-pair tests.
Results between groups were analyzed using the Kruskal-Wallis with Dunn’s post-test and the Mann–Whitney U tests.
Results: None of the study participants had evidence of enteric co-infections as assessed by stool analysis and
histology. Compared to healthy HIV-negative controls, the colon of AIDS patients was highly inflamed with increased
infiltration of inflammatory cells and increased mRNA expression of proinflammatory cytokine (tumour necrosis factor
(TNF)-α, interleukin (IL)-1β, IFN-γ, and IL-18), chemokines (chemokine (C-C motif) ligand (CCL)2 and chemokine (C-X-C)
motif ligand (CXCL)10) and transcription factors (TNF receptor-associated factor (TRAF)6 and T-box (TXB)21). IHC
revealed significant co-localization of TNF-α and IL-1β with CD68+ cells. As in IBD, HIV was associated with a marked
increase in macrophages expressing innate response receptors including CD14, the co-receptor for lipopolysaccharide
(LPS). The frequency of CD14+ macrophages correlated positively with plasma LPS, a marker of MT. Total unfractionated
mucosal mononuclear cells (MMC) isolated from the colon of AIDS patients, but not MMC depleted of CD14+ cells,
secreted increased levels of proinflammatory cytokines ex vivo in response to LPS.
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Conclusions: Intestinal macrophages, in the absence of overt OIs, play an important role in driving persistent
inflammation in HIV patients with late-stage disease and diarrhea. These results suggest intensified treatment
strategies that target inflammatory processes in intestinal macrophages may be highly beneficial in restoring
the epithelial barrier and limiting MT in HIV-infected patients.
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Background
The human immunodeficiency virus type (HIV) induces
rapid and profound damage to the gut-associated lymph-
oid tissue (GALT). Damage includes an early massive
depletion of the T helper (Th)17 subset of CCR5+CD4+
memory T cells [1–7], changes in the frequency of
CD4+CD25+FoxP3+ T regulatory (Treg) cells [8–10], an
influx of activated cytotoxic CD8+ T lymphocytes [11],
irreversible activation-induced fibrosis [12, 13] and a loss
of epithelial integrity leading to increased microbial
translocation (MT) [14]. MT is a major cause of local
and systemic immune activation in HIV-infected pa-
tients, both before and during antiretroviral therapy
(ART) [14–17].
Clinical manifestations of HIV infection in the gastro-
intestinal tract include malabsorption, diarrhea and a
wasting syndrome [18–21]. Diarrhea accompanied by
wasting (“slims disease”) is responsible for a significant
amount of HIV-related morbidity in sub-Saharan Africa
[22], even in the era of ART [23, 24]. Opportunistic in-
fections (OIs) are a common cause of these disorders in
HIV-infected individuals and include a range of viral,
bacterial, fungal and parasitic pathogens [24]. Cotrimox-
azole prophylaxis is a mainstay for the prevention of OIs
in Africa and other resource limited settings and is rec-
ommended for severely immunocompromised HIV-
infected individuals [25]. Prophylactic treatment with
cotrimoxazole has been shown to improve survival and
reduce morbidity in HIV patients prior to the initiation
of ART [25–28].
Intestinal macrophages play a pivotal role, not only in
the recognition and elimination of invading pathogens,
but also in the regulation of inflammatory responses,
maintaining the integrity of the epithelial barrier and in
tissue remodeling and repair [29–33]. Under homeo-
static conditions, stromal factors such as transforming
growth factor-β (TGF-β), induce intestinal macrophages
to differentiate into “inflammation anergic” cells that
promote tolerance by maintaining the expression of
Foxp3 in suppressive Treg cells [34]. These “resident”
macrophages have avid phagocytic and bacteriocidal ac-
tivity but do not express innate response receptors or
co-stimulatory molecules and do not produce inflamma-
tory cytokines in response to microbial stimulation [29,
35]. Inflammation anergy plays a central role in
preventing damage to the gastrointestinal tract, an organ
that is constantly exposed to a large number of com-
mensal bacteria and other antigenic stimuli.
However, under conditions of chronic inflammation,
intestinal macrophages can develop a pro-inflammatory
phenotype and secrete inflammatory mediators such as
TNF-α, interleukin-Iβ (IL-1β), interleukin-6 (IL6), and
nitric oxide in response to invading pathogens and anti-
genic stimuli. Failure to downregulate this inflammatory
response, as observed in patients with IBD and cirrhosis,
is a major driver of intestinal disease [29, 36, 37]. Pro-
inflammatory macrophages in the colon of patients with
Crohn’s disease express CD14, produce inflammatory
mediators in response to Toll-Like Receptor (TLR)
stimulation and contribute to chronic intestinal inflam-
mation via induction of the interleukin-23/interferon-γ
(IL-23/IFN-γ)–positive feedback loop [29]. The accumu-
lation of CD14+ macrophages in patients with Crohn’s
disease has been attributed to an increased recruitment
of inflammatory monocytes and a concomitant dis-
ruption of physiological, tissue-specific macrophage dif-
ferentiation [38]. Consistent with these findings, a recent
study of the duodenum has shown that HIV infection is
associated with increased production of macrophage-
related pro-inflammatory molecules (IL-1β, CCL5, CXCL9,
and CXCL10) and enrichment of macrophages with low
phagocytic activity [39].
In this study, we evaluated the inflammatory milieu
and characterized the phenotypic and functional properties
of macrophages in the colon of cotrimoxazole-treated
ART-naïve African AIDS patients with unexplained diar-
rhea and/or weight loss who had no evidence of a con-
founding co-infection. Results were compared to those
obtained in HIV-negative African controls with and without
IBD. We detected a marked increase in pro-inflammatory
macrophages in the colon of AIDS patients compared to
healthy HIV seronegative controls. These cells expressed
CD14 and other innate response receptors and produced
inflammatory cytokines (TNF-α and IL-6), both constitu-
tively and in response to LPS stimulation.
Methods
Study participants
The initial study cohort consisted of 23 cotrimoxazole-
treated, ART-antiretroviral therapy naïve AIDS patients
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who were undergoing diagnostic endoscopy for unex-
plained diarrhea (>12 weeks duration) and weight loss
(>10 % of the patient’s body weight). Five additional
HIV-infected patients were subsequently sampled for
ex vivo studies of LPS stimulation and cytokine/chemo-
kine production. All patients had been receiving on
Cotrimoxazole for >6 months. After obtaining written
informed consent, biopsies were collected from the as-
cending and descending colon using a standard colono-
scope and were processed for flow cytometry and
histological evaluation. Blood samples were collected
for routine patient management [CD4+ and CD8+ T cell
counts, plasma viral load (VL)] and for quantification
of plasma LPS. Patients were eligible for the study if
they tested negative for Mycobacterium tuberculosis
and for enteric pathogens in stool specimens. Subjects
with secondary gastrointestinal infections, as deter-
mined by culture and microscopic examination of stool
specimens and by histological evaluation of biopsies
were excluded from the study. Clostridium difficile was
excluded using three different methods - enzyme im-
munoassay for toxins A and B, PCR and histopathology.
Healthy HIV-seronegative South Africans (n = 5) who
tested pathogen negative and showed no evidence of
disease during screening for colorectal cancer served as
controls. These subjects were matched to HIV subjects
by age and gender (median age 34, range 26–45 years;
60 % male). Six HIV-negative South Africans with in-
flammatory bowel disease (IBD) and symptoms of disease
activity including abdominal cramps, diarrhea or
bloody stools were also recruited. None of the IBD
patients had received corticosteroids, azathioprine, 6-
Mercaptopurine (6-MP) or anti-TNF therapy during
the 6 months prior to enrollment. Following informed
consent, biopsies were obtained from areas of active
colitis. The study was reviewed and approved by the
Research Ethics Committee of the Faculty of Health
Sciences, University of Pretoria.
Specimen collection and processing
Biopsies were collected prior to ART. A total of 8–10
“pinch biopsies” were collected from each patient. Biop-
sies were placed on ice in tissue culture medium RPMI
1640 supplemented with 10 % fetal calf serum (FCS) and
immediately processed for flow cytometry or in vitro
stimulations. Biopsies for immunohistochemistry (IHC)
were fixed in 10 % neutral buffered formalin and embed-
ded in paraffin; biopsies for PCR array were snap frozen
in liquid nitrogen and stored at −80 °C.
Histological analyses
Hematoxylin and eosin (H&E), periodic acid-Schiff
diastase (PAS-d), Ziehl-Neelsen and Giemsa staining
were performed to exclude acid fast bacilli (AFB), fungal
and parasitic organisms (including Cryptosporidium and
Isopora, spp., as well as Microsporidia). Cytomegalo-
virus, adenovirus and herpes simplex virus were ex-
cluded by careful scrutiny of H&E slides supplemented
with appropriate IHC staining. Clostridial infection was
excluded on morphologic grounds by means of careful
evaluation of H&E sections. For T cell quantification, tis-
sue sections were incubated with murine anti-human
CD4 (clone 4B12, DAKO, Denmark) or CD8 (clone
CD8/CD144B, DAKO, Denmark) monoclonal antibodies
(mAbs), visualized with 3,3′-Diaminobenzidine (DAB) and
counter-stained with haematoxylin. CD68 (KP1, DAKO,
Denmark), CD14 (M0825 clone TUK4, DAKO), IL-1β
(Abcam ab8320), IL-6 (Abcam ab9324) and TNF (Pepro-
Tech 500-M26) staining was performed on sections re-
trieved in PT101 Link Pre-Treatment Module (Dako), as
previously described [37]. Following blocking of endogen-
ous peroxidase and incubation with rabbit polyclonal anti-
CD14 Ab or with mouse mAbs directed against CD68,
IL1β, IL-6 or TNF-α, tissue sections were treated with
Envision™/Horseradish peroxidase (HRP) dual link polymer,
visualized with DAB+ chromogen and counter-stained with
hematoxylin. IHC staining on two colonic biopsies per
patient was evaluated, with the area on the slides showing
the most positivity used for evaluation. The number of
positive cells in 5 contiguous high power fields (HPF)
of 0.80 mm2 (magnification x 400) was counted and
reported as the average number of macrophages/HPF.
Images were acquired, recorded and processed using
a Leica DMLB 11888011 microscope and digital cam-
era and an IM50 Image Manager (Leica Microsystems
Wetzlar, GmbH, Germany). To determine if CD68+ mac-
rophages were producing inflammatory cytokines, colonic
biopsies were subjected to sequential double labeling with
Abs directed against CD68 and either IL1β or TNF-α
using established methods [37]. Slides were incubated
with anti-human IL1β or TNF-α primary Ab, washed and
incubated with Alexa Fluor-488-conjugated secondary Ab
(Invitrogen). After boiling and treatment with 3 % H2O2/
methanol to block the antigenicity of the first set of Abs,
the staining procedure was repeated using mouse anti-
human CD68 and Alexa Fluor-568-conjugated secondary
Ab (Invitrogen). Nuclei were stained with DAPI. The opti-
mal concentration of each primary antibody (either mouse
anti-IL1β or anti-TNF-α, or in the case of the second pri-
mer set, mouse anti-CD68) was determined using positive
(tissue sections from patients with acute intestinal in-
flammation) and negative (reagents lacking primary
antibody) controls and a dilution series of the primary
antibody of interest. Data acquisition was performed
using a Zeiss Axioplan 2 fluorescent microscope
equipped with a triple filter, Fluoarc fluorescent light
source and Axiocam ICc1 camera. All studies were
performed in a blinded fashion by a histopathologist
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with extensive experience in the analysis of intestinal
specimens.
Phenotyping of Mucosal Mononuclear Cells (MMC)
MMC were obtained by digesting the biopsies in RPMI
1640 containing 10 % FCS and 0.5 mg/ml collagenase
type IV (Sigma, St Louis, MO) for 30 min at 37 °C as
previously described [40]. The resultant single cell sus-
pensions were passed through a 70-μm cell strainer to
remove debris (Becton Dickenson, Labware, NJ). The
remaining tissue fragments were re-digested and pooled
digests were strained, washed and processed for flow
cytometry or LPS stimulation. Multi-parameter flow cy-
tometry was performed on digested colonic MMC (0.5
x106 cells/tube) that had been stained for 30 min at 4 °C
with various combinations of anti-human CD3, CD4,
CD8, CD33, CD14, CD16, CD80, and CD86 mAbs
(Beckman Coulter Inc., Fullerton, CA). T cell popula-
tions were identified based on forward and side-scatter
characteristics and expression of CD3. Macrophage pop-
ulations were identified based on forward and side scat-
ter characteristics and the expression of CD33. CD14,
CD16, CD80 and CD86 levels were determined by gating
on CD33+ cells. CD33+ cells were confirmed to be posi-
tive for plasma membrane CD45 and CD68 by back gat-
ing during the initial establishment of flow cytometry
protocols. Samples were analyzed on a Beckman Coulter
FC500 flow cytometer with a minimum of 5000 gated
events collected per tube. Results were analyzed using
Flow Jo (Tree Star, Ashland, OR).
PCR array
Expression levels of 84 inflammatory genes were deter-
mined using the human Th17 Autoimmunity and In-
flammation RT2 Profiler PCR array (SABioscience,
Frederick, MD). Total RNA was extracted from 12 to
15 mg of colonic tissue using the Maxwell® 16 Tissue
LEV Total RNA Purification Kit. cDNA was synthesized
from 0.5 μg of total RNA using the RT2 PCR array first
strand kit. Real time PCR was performed in 96-well
plates using RT2 SYBR Green qPCR Master Mix and a
CFX96 Real Time PCR Detection System (BioRad,
Hercules, CA). Ten AIDS patients, 6 IBD patients and 5
HIV negative controls were analyzed in triplicate. Re-
sults were normalized using 5 housekeeping genes and
analyzed by the comparative cycle threshold method.
Quantification of plasma LPS
Peripheral venous blood was collected in EDTA tubes at
the time of colonoscopy. Plasma was isolated by centri-
fugation at 1800 rpm for 10 min at 4 °C and stored in
1.0 mL aliquots at −80 °C. LPS levels were quantified
using the Limulus Amoebocyte Lysate assay QCL-1000
(Lonza, Valais Switzerland) and expressed as EU/mL as
previously described [15].
LPS stimulation of CD14+ and CD14− MMC
CD14+ macrophages were depleted from colonic MMC
by positive selection (CD14 Microbeads, Miltenyi Bio-
tech). Total MMC and CD14− MMC (0.25x106 cells/
well) were cultured in triplicate in RPMI/10 % FCS/5 %
human AB serum in the presence or absence of LPS
(1 μg/mL; Sigma) for 18 h. Cytokine and chemokine
levels (pg/ml) in culture supernatants were quantified
using the Bio-Plex Suspension Array System according
to manufacturer’s instructions (Bio-Rad).
Statistical analyses
Prism 5 from GraphPad Software (La Jolla, CA) was
used for statistical analyses. Paired observations were
compared using Wilcoxon matched pair tests. The
Kruskal-Wallis with Dunn’s post-test or Mann–Whitney
U tests were used to compare between groups. Linear
correlations were assessed using Spearman’s rank correl-
ation coefficient. Two-tailed p values <0.05 were consid-
ered significant. PCR array fold change calculations were
performed using the RT2 Profiler PCR Array Data Ana-
lysis Template v3.2 (SABioscience).
Results
Patient characteristics
Clinical characteristics of the AIDS study cohort (n = 23)
are shown in Table 1. All patients had high plasma VLs
(median 5.08 (4.2–6.6) log10 HIV RNA copies/mL) and
low blood CD4+ T cells counts (median 69 (6–237)
cells/uL). Symptoms leading to endoscopy were chronic
diarrhea in 13 (56 %) and/or unexplained weight loss in
10 (44 %) patients. Five additional AIDS patients were
subjected to ex vivo stimulation studies. None of the 28
patients had evidence of enteric co-infections as assessed
Table 1 Clinical characteristics of African AIDS patients with
unexplained diarrhea and/or weight loss
Age Mean ± S.D. 35 ± 11
Median (Range) 33 (21–52)
Gender Male 12 (52 %)
Female 11 (48 %)
CD4 count (cells/μl) Mean ± S.D. 90 ± 68
Median (Range) 69 (6–237)
% CD4 cells Mean ± S.D. 8.5 ± 5.5
Median (Range) 7.4 (0.42–22.7)
log10 HIV RNA copies/ml Mean ± S.D. 4.89 ± 0.97
Median (Range) 5.08 (4.2–6.6)
GIT complications Diarrhea 13 (56 %)
Weight loss 10 (44 %)
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by stool analysis and histology. HIV-negative healthy
controls (n = 5) showed no evidence of structural dam-
age or inflammatory cell infiltrates. HIV-negative IBD
patients had typical well-documented Crohn’s disease
(CD; n = 3), or ulcerative colitis (UC; n = 3) that included
granulomatous lesions, ulcerations and gross structural
damage to the colon.
The colon of AIDS patients with unexplained diarrhea
and/or wasting contains inflammatory cell infiltrates and
increased levels of pro-inflammatory cytokines
Understanding the potential contribution of intestinal
macrophages to HIV-induced pathogenesis requires a
comprehensive analysis of the local microenvironment.
The current study was performed on a relatively homo-
geneous population of co-pathogen negative ART-naïve
patients with late-stage disease. As in previous studies
[40], there was a dramatic reduction in the number CD4
+ T cells and a corresponding increase in CD8+ T cell
numbers in the colon of AIDS compared to HIV-
negative IBD patients and healthy controls (CD4 counts:
median of 13 vs. 72 vs. 63 cells/0.8 mm2, respectively;
CD8 counts: median of 84 vs. 39 vs. 59 cells/0.8 mm2 re-
spectively) (Fig. 1a and b). Mild-to-moderate non-
specific colitis, as measured by the infiltration of inflam-
matory cells, namely CD8+ T cells, eosinophils and
plasma cells, was detected in the colon of AIDS patients.
IHC staining indicated that there was a marked increase
in proinflammatory cells expressing IL-1β (median 174
vs. 75 cells/0.8 mm2, p = 0.04) and TNF-α (median 226
vs. 107 cells/0.8 mm2, p = 0.01) in the colon of AIDS pa-
tients compared to healthy controls (Fig. 1c and d).
Thus, diarrhea and wasting were associated with in-
creased recruitment of inflammatory cells and increased
pro-inflammatory cytokine production, even in the ab-
sence of overt OIs.
Genes involved in macrophage activation and Th1
responses are preferentially up-regulated in the colon of
AIDS patients
We next assessed changes in mRNA expression in total
colonic tissue isolated from AIDS patients (n = 10), HIV-
negative IBD patients (n = 6) and HIV-negative healthy
controls (n = 5). Out of 84 genes tested using the Human
Th17 for Autoimmunity and Inflammation PCR array
(SABioscience), 23 were abnormally expressed in the
colon of AIDS and/or IBD patients (Table 2). IL-18,
CCL2, TRAF6 and IL-12Rβ1 were upregulated in both
AIDS and IBD patients compared to controls. Consistent
with IHC results, there was a significant increase in
TNF-α (FC 7.11, p = 0.05) and IL-1β (FC = 4.27, p = 0.05)
mRNA in AIDS patients compared to controls. HIV
infection was also associated with increased expression
of genes involved in chemotaxis and activation of
monocytes/macrophages (CCL2 and TRAF6) and Th1
responses (IFN-γ and TBX21) as reported in Table 2.
Genes associated with maintaining tissue homeostasis
and an anti-inflammatory environment (ie. IL-10, TGF-
β1 and suppressor of cytokine signaling (SOCS)3) were
unchanged in AIDS patients, but increased in HIV-
negative subjects with IBD, a finding that is suggestive of
a tissue-protective response in these patients (Table 2).
Thus, chronic diarrhea and/or weight loss in African
AIDS patients is associated with increased levels of
macrophage related cytokines (TNF-α and IL-1β) and
chemokines (CCL2) compared to HIV-negative healthy
controls.
Macrophages in the colon of AIDS patients produce
TNF-α and IL-1β and have an activated CD14+ phenotype
To determine whether macrophages were contributing
to the pro-inflammatory milieu in the colon of AIDS pa-
tients, we performed double labeling of CD68+ macro-
phages with TNF-α and IL-1β using a dye swap method
with validation by fluorescence microscopy [26]. TNF-α+
and IL-1β+ CD68-positive macrophages were present in
the lamina propria of AIDS patients (Figs. 2 and 3). As
in CD, there was a marked increase in CD14+ macro-
phages in the colon of AIDS patients compared to HIV-
negative controls. The absolute number of CD14+ cells,
as determined by IHC, increased from 1.8 cells/HPF in
controls to 55 cells/HPF (p = 0.004) in patients with
AIDS; the percentage of CD14+ cells, as assessed by flow
cytometry using CD33, increased from a median 6.5 to
21.2 % (p =0.007) (Fig. 4). In addition to CD14, CD33+
macrophages in AIDS patients co-expressed the Fc re-
ceptor γ (CD16) and T cell the co-stimulatory molecules
CD80 and CD86 (Table 3). Of considerable interest was
the detection of a positive correlation between the per-
centage of CD14+CD33+ colonic macrophages and the
levels of plasma LPS (R = 0.67, p = 0.002). The percent-
age of CD14+CD33+ colonic macrophages did not cor-
relate with any other clinical variable or marker of
inflammation (e.g., plasma or tissue HIV viral load, CD4
count, age). Collectively, these findings indicate that
macrophages in the colon of African AIDS patients with
diarrhea and/or weight loss have an activated CD14+
phenotype and express pro-inflammatory cytokines
(TNF-α, IL-1β) that are known to be induced by
LPS–mediated activation of CD14+ macrophages [41].
LPS stimulation induces increased production of
macrophage related pro-inflammatory cytokines in MMC
isolated from the colon of AIDS patients
To assess the LPS responsiveness of colonic immune
cells, total and CD14-depleted MMC isolated from the
colon of 10 HIV+ patients and 5 healthy controls were
cultured in vitro for 18 h in the presence or absence of
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LPS. Secretion of cytokines and chemokines into the
culture supernatant was measured using customized
Bio-Plex plates. In the absence of LPS, unstimulated
total MMC from AIDS patients secreted significantly
higher levels of macrophage related pro-inflammatory
cytokines (TNF-α and IL-6) and chemokines (CCL2,
CXCL10) compared to the MMC isolated from healthy
controls (Fig. 5). LPS stimulation of total MMC from
AIDS patients induced a further increase in TNF-α
(median: 17.9 vs 31.8 pg/mL in unstimulated vs. stimu-
lated MMC, respectively, p = 0.031) and IL-6 (median:
19.3 vs 45.46 pg/mL, respectively, p = 0.006) secretion.
In contrast, LPS failed to increase CCL2 and CXCL10
secretion in MMC, suggesting that the upregulation of
these chemokines is controlled by an LPS-independent
mechanism. When MMC from AIDS patients were de-
pleted of CD14+ cells (ie. CD14− MMC), they produced
less TNF-α (median: 9.7 pg/ml, p = 0.032) and IL-6 (me-
dian 2.2 pg/mL, p = 0.002) than unfractionated MMC,
suggesting that CD14+ macrophages played a major role
in the expression of these pro-inflammatory cytokines
(Fig. 6). Unlike CD14+ MMC, LPS had no inductive
a b
c
d
P=0.008
P=0.002 P=0.016 P=0.019
Fig. 1 Inflammation in the colon of AIDS patients occurs in the setting of severe T cell dysregulation. a Differences in the frequency of CD4+ T in
the colon of AIDS patients (n = 23) relative to uninfected healthy controls (n = 5) and IBD patients (n = 5) as determined by IHC. b Increased
number of CD8+ T cells in the colon of AIDS patients relative to controls (p = 0.016) and patients with IBD (p = 0.019), as determined by IHC.
Graphs show the median values and statistical significance between groups as calculated by Kruskal-Wallis with Dunn’s post-test. c Representative
IHC staining showing increased levels of IL-1β in the colon of AIDS patients vs. uninfected controls (p = 0.04). d IHC staining showing increased
TNF-α expression in the colon of AIDS patients compared to controls (p = 0.01)
Cassol et al. BMC Infectious Diseases  (2015) 15:430 Page 6 of 13
effect on cytokine production in CD14-depleted MMC.
These results suggest that CD14+ macrophages in the
colon of African AIDS patients presenting with diarrhea
and/or weight loss may have increased responsiveness to
microbial products, a finding that would be expected to
perpetuate the local inflammatory response.
Discussion
In this study, we used several different in situ (IHC) and
ex vivo (flow cytometry, cytokine/chemokine production,
mRNA profiling) methods to assess the phenotype and
functional parameters of macrophages in the colon of
ART-naïve African AIDS patients with unexplained
gastrointestinal symptoms. Despite prophylactic treat-
ment with cotrimoxazole and the apparent absence of
OIs, we found that the colon of AIDS patients with
chronic diarrhea and/or weight loss was highly inflamed
and contained increased numbers of inflammatory cell
infiltrates. The total expression of cytokines, chemokines
and transcription factors associated with macrophage
recruitment and activation was also significantly
increased in the colon of AIDS patients compared to
negative controls. The pattern of cytokine/chemokine
upregulation in these patients was similar to that ob-
served in HIV-negative subjects with CD. In addition,
we detected a significant increase in activated CD14+
macrophages that produced pro-inflammatory cytokines
and were responsive to LPS stimulation supporting the
view that, as in CD [30, 32, 36], disrupted or abnormal
differentiation of macrophages may be a major cause of
the excessive inflammation and loss of tolerance to com-
mensal bacteria that is observed in HIV-infected pa-
tients. While we did not observe any direct associations
between the levels of CD14+ macrophages and tissue or
plasma HIV viral loads, we speculate that high levels of
HIV replication in the gastrointestinal tract during acute
infection results in increased the recruitment of inflam-
matory monocytes. Unlike resident tissue macrophages,
these newly recruited cells differentiate into macro-
phages that produce pro-inflammatory cytokines and
Table 2 Fold changes in mRNA levels of immune mediators altered in African AIDS patients and in patients with IBD
HIV vs. Controls CD vs. Controls UC vs. Controls
FC p-value FC p-value FC p-value
Cytokines and Chemokines IFN-γ 5.31 0.001 4.81 0.037 1.02 0.667
TNF-α 7.11 0.005 14.27 0.001 13.65 0.001
IL-1β 4.27 0.050 12.97 0.032 59.26 0.049
IL-8 7.24 0.212 36.84 0.075 194.5 0.002
IL-10 3.03 0.376 4.19 0.123 5.44 0.012
IL-18 26.85 0.031 32.17 0.004 28.57 0.001
TGF-β1 2.55 0.542 3.46 0.029 4.04 0.045
CCL2 10.78 0.008 16.07 0.007 59.33 0.009
CCL22 1.40 0.697 3.61 0.043 1.94 0.491
CXCL2 1.77 0.387 2.25 0.447 3.23 0.097
Receptors ICAM1 4.31 0.231 14.17 0.008 31.75 0.001
IL12Rβ1 3.69 0.017 4.06 0.026 3.42 0.045
TLR4 3.28 0.192 5.05 0.211 6.16 0.042
IL6R 1.09 0.782 1.14 0.541 0.66 0.037
IL17RE 0.64 0.521 0.67 0.245 0.38 0.041
IL17Rβ 0.76 0.469 0.27 0.037 0.15 0.006
Transcription Factors TRAF6 14.75 0.014 12.77 0.027 12.81 0.049
SOCS1 2.29 0.512 4.24 0.076 8.27 0.029
SOCS3 1.96 0.341 5.52 0.023 20.31 0.005
S1PR1 3.12 0.231 4.29 0.049 7.15 0.009
TBX21 5.73 0.012 4.04 0.038 2.53 0.234
YY1 11.91 0.046 5.84 0.071 7.97 0.001
CLEC7 2.09 0.432 2.49 0.381 4.84 0.043
IFN-γ Interferon-γ, TNF-α Tumour Necrosis Factor-α, IL Interleukin, TGF-β1 Transforming Growth Factor-β1, CCL Chemokine (C-C motif) ligand, CXCL chemokine
(C-X-C motif) ligand, TLR Toll-like receptors, SOCS suppressor of cytokine signaling proteins, TRAF TNF receptor associated factor, TBX T-box transcription factor, YY
Yin Yang, CLEC C-type lectin domain family
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chemokines in response to bacterial and viral products.
Production of these pro-inflammatory mediators, to-
gether with residual viral replication and ongoing re-
cruitment and differentiation of monocytes into pro-
inflammatory macrophages, leads to further propagation
of the inflammatory response a process that continues
throughout the course of infection.
In the current study, we observed increased recruit-
ment of inflammatory cell infiltrates (CD8+ T cells, eo-
sinophils and/or plasma cells) and increased production
of pro-inflammatory cytokines (including TNF-α and IL-
1β) in the colon of ART-naive patients with late-stage
HIV infection. At the mRNA level, we detected a signifi-
cant increase in transcripts coding for pro-inflammatory
cytokines and their receptors (TNF-α, IL-1β, IL-18, IFN-
γ, IL-12RB1), chemokines (CCL2, CXCL10) and
inflammation-related transcription factors (TRAF6,
TXB21, YY1) in AIDS patients compared to HIV-
negative controls. These findings are consistent with
North American and European studies showing in-
creased expression of pro-inflammatory cytokines in the
rectosigmoid colon and duodenum of ART-naïve pa-
tients [39, 42, 43] with peak expression of TNF-α and
IL-1β mRNA in the rectum occurring in patients with
AIDS [44]. Our data is also consistent with studies
showing increased expression of chemokines (CCL5,
CXCL9, and CXCL10) in the duodenum of untreated
HIV-infected patients [39]. Many of the immune media-
tors expressed at high levels in AIDS patients were also
up-regulated in patients with CD (TNF-α, IL-1β, and
IFN-γ) and have been implicated in the pathogenesis of
CD [45]. As observed for HIV, CD is associated with sys-
temic inflammation and increased plasma levels of
markers of microbial translocation [46–48]. In CD, these
changes are associated with increased secretion of IL-12
by activated intestinal macrophages. Higher levels of IL-
12 drive increased production of IFN-γ in T cells, in-
creased epithelial permeability and further enhancement
of macrophage activation and microbial translocation
[29]. Given the marked increase in IFN-γ observed in
the colon of AIDS patients, it is conceivable that a
similar feedback loop may be occurring in ART-naïve
patients with advanced HIV infection.
Phenotypic and functional characterization of intes-
tinal macrophages indicated that there was marked a in-
crease in a unique subset of pro-inflammatory (CD14+)
mononuclear phagocytes in the colon of cotrimoxazole-
treated ART-naïve AIDS patients compared to un-
infected controls. As in CD, these mononuclear phago-
cytes produced TNF-α and IL-1β and expressed innate
response receptors including CD14, the co-receptor for
LPS. Although these cells are believed to be macro-
phages based on their expression of CD33 and CD68, we
cannot exclude the possibility that they may also have
CD68
TNFa merged
DAPI
Fig. 2 Macrophages in the colon of AIDS patients with unexplained
diarrhea and/or weight loss produce TNF-α. Fluorescence microscopy
of colon tissue from ART-naive AIDS patients dually stained with
anti-CD68 (green) and anti-TNF-α (red) mAbs showing TNF-α+CD68+
macrophages in the lamina propria
DAPI
Merged
CD68
IL1b
Fig. 3 Macrophages in the colon of AIDS patients with unexplained
diarrhea and/or weight loss produce IL-1β. Fluorescence microscopy
of colon tissue from ART-naive AIDS patients dually stained with
anti-CD68 (green) and anti-IL-1β (red) mAbs showing IL-1β+CD68+
macrophages in the lamina propria
Cassol et al. BMC Infectious Diseases  (2015) 15:430 Page 8 of 13
some properties of myeloid dendritic cell (mDC). Studies
by Kamada et al. have reported that CD14+CD33+CD68+
“macrophages” in the colon of CD patients co-express the
mDC markers, CD205 and CD209 (DC-SIGN) [29, 30].
Ex vivo studies of total MMC (containing CD14+ mac-
rophages) isolated from the colon of AIDS patients indi-
cated that these cells secreted increased levels of TNF-α,
IL-6, CCL2 and CXCL10 compared to HIV-negative
Gate 1 Gate 2b
a
c d
e
Fig. 4 CD14+ macrophages accumulate in the colon of AIDS patients despite cotrimoxazole prophylaxis and absence of co-infections. a Representative
IHC staining showing higher levels of CD14 expression on colonic macrophages of AIDS patients vs. uninfected healthy controls. b Representative
histogram from flow cytometric analysis showing gating strategy and co-expression of CD14 in CD33+ cells. c Quantification of IHC analysis showing
increased levels of CD14+ cells in the colon of AIDS patients relative to uninfected healthy controls; the median values and the statistical significance
of the analysis between the two groups (p = 0.004) are indicated. d Summary of flow cytometric analyses showing increased expression of CD14 on
CD33+ macrophages isolated from the colon of AIDS patients vs. uninfected healthy controls; the median values and the statistical significance of the
analysis between the two groups are as indicated (p = 0.007). e Spearman correlations (R and p values) showing positive correlation between CD14+
macrophages in the colon of these patients and plasma levels of LPS (right panel). Results were considered significant if p < 0.05. Correlations were
considered strong if r >0.6
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controls. Removal of CD14+ cells resulted in a marked
decrease in the ability of MMC to produce pro-
inflammatory cytokines suggesting that CD14+ macro-
phages are an important source of pro-inflammatory
mediators in ART-naïve patients with late-stage HIV in-
fection. Macrophages isolated from AIDS patients also
had an increased ability to respond to microbial prod-
ucts including LPS, a TLR4 ligand, presumably due to
the upregulation of CD14 and other innate response re-
ceptors. The positive correlation observed between
CD14+ macrophages and plasma LPS suggests that the
increased frequency of these cells in the colon of AIDS
patients is linked to MT. Additional studies will be re-
quired to determine whether CD14+ macrophages are
responsive to TLR-ligands other than LPS and to better
define the relationship between CD14+ macrophages and
microbial translocation. Studies are also needed to assess
the phagocytic properties of CD14+ macrophages in the
colon of African AIDS patients. A recent study by Allers
et al., has shown that mononuclear cells isolated from
the duodenum of HIV-infected patients have a reduced
ability to phagocytose E coli BioParticles and thus, may
be less likely to eliminate antigenic and microbial
products that have crossed the epithelial barrier [39].
The strengths of our study relate to the homogeneity
of our patient cohort with respect to treatment, stage of
infection, viral load and CD4+ T cell counts. Limitations
relate to the small size of our positive (IBD) and negative
control groups. In addition, despite efforts to exclude pa-
tients with enteric co-infections (cotrimoxazole prophy-
laxis, stool culture and histological staining for acid-fast
bacilli, fungal and parasitic infections), we cannot rule
out the possibility that opportunistic co-infections may
have affected our results. Additional studies are needed
to determine whether our results can be extended to pa-
tients with early HIV infection and ART-treated patients
with and without enteric co-infections. Studies exploring
the relationships between increased inflammatory
macrophage infiltrate and alterations in the functional
gene content of intestinal microbiota are also of major
importance given the vital role of the microbiota in
shaping the intestinal microenvironment.
Conclusions
We have demonstrated that the colon of cotrimoxazole-
treated ART-naïve AIDS patients contains increased
numbers of activated CD14+ pro-inflammatory macro-
phages and that these cells are responsive to bacterial
Table 3 Phenotypic characterization of colonic macrophages as determined by flow cytometry
CD14+ (median % of CD33+ cells) CD16+ (median % of CD33+ cells) CD80+ (median % of CD33+ cells) CD86+ (median % of CD33+ cells)
HIV− 6.5 ± 4.8 11.1 ± 7.6 9.2 ± 5.5 15.1 ± 7.3
HIV+ 21.2 ± 11.7 19.4 ± 12.5 25.1 ± 15.4 23.7 ± 18.1
HIVControl HIVControl
UNSTIMULATED
LPS
Control HIV
p=0.031 p=0.006
Control HIV
Fig. 5 LPS induces increased pro-inflammatory cytokine production by MMC isolated from the colon of AIDS patients. Total MMC isolated from
the colon of African AIDS patients (n = 10) and healthy uninfected healthy controls (n = 5) were cultured for 18 h in the presence or absence of
LPS. Cytokine and chemokine levels in the culture supernatants were quantified using customized Bio-Plex plates from BioRad. The results represent
the mean ± SD of two independent experiments performed in triplicate. Statistical significance between groups was calculated using the
Mann–Whitney U test. Statistically significant differences (p < 0.05) are indicated by an asterisk
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LPS and linked to MT. This study underscores the simi-
larities between HIV and non-infectious IBD and high-
lights the need for detailed comparative studies to
determine if there is a common mechanism driving
these inflammatory pathologies. It will be especially im-
portant to determine whether the persistence of inflam-
mation and immune activation in cotrimoxazole-treated
patients is driven by HIV replication or by alterations in
the intestinal microenvironment (such as changes in the
microbiome [49, 50]; irreversible (or reversible) damage
to the intestinal epithelium and/or non-specific activa-
tion of CD8+ T cells). This information is needed to
design highly targeted treatments that can restore the
integrity of the intestinal epithelium, normalize the
intestinal microbiota and prevent MT.
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